Status: Recruiting
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Participants needed: 140
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nuvectis Pharma, Inc.Updated: Mar 3, 2026Locations: 12
Eligibility criteria
Provide written informed consent. [+4]
Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpress... [+25]